An Observational Study of the Prevalence of Patients Requiring Palliative Care in French Anti-cancer Centers. (PREPA-10)
An Observational Study of the Prevalence of Patients Requiring Palliative Care in the French Anti Cancer Centers.
The purpose of this observational study is to determine the proportion of patients with a score greater than 3/10 to the questionnaire PALLIA-10.
This questionnaire is a tool provided by the French Society for Palliative Cares, aiming at helping the providers of care to identify patients who would require palliative cares.
According to the notice of the questionnaire, patients with a score greater than 3 would be taken in charge by a palliative care team. Considerong the 10 itmes of this questionnaire, it seems that a large majority of patients would have a score greater than 3 in the context of anti cancer centers.
To date, palliative teams are not designed to take in charge such an amount of patients.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Continuous improvement of therapeutics helped to lengthen different stages of natural cancer evolution. Advanced cancer patients are followed-up even longer; therefore there is a need to increase palliative care resources. A global therapeutic approach is being set up gradually thanks to specialized supportive care team. This global approach includes therapeutics and life condition improvement of the patient and his family.
In France, only 2 anti-cancer centers have a palliative care unit. The 16 other centers design hospital beds for palliative care and work with mobile palliative care teams.
According to latest studies with high level of evidence, International oncology societies published good practices guidelines supporting the need of early palliative cares for patients with metastatic cancer.
In 2010, Temel et al. demonstrated early palliative care effectiveness. Indeed, early palliative care led to significant improvements in both quality of life (score on the FACT-L scale: 98.0 vs. 91.5; p=0.03) and mood (depressive symptoms: 16% vs. 38%, P=0.01). Moreover median survival was longer among patients receiving early palliative care (11.6 months vs. 8.9 months, p=0.02). Analysis showed that patients assigned to early palliative care stopped chemotherapy earlier, had a higher enrollment rate in palliative care units and less depressive symptoms when cares were provided by both oncologists and palliative care teams.
Other specific scales support efficiency of early palliative care on quality of life. Early palliative care increases also satisfaction of the cares. Therefore, these results illustrate the need for an early integration of palliative care in France; and this approach is recommended in the third national plan against cancer.
Despite efficacy data, no high international consensus exists on a screening score for patients requiring early palliative care. Some teams therefore use prognostic factors like Barbot score.
Confronted with such difficulties, the French Society for Counselling and Palliative Care create a score (PALLIA-10) with 10 items on personal situation of the patient and his disease. This score helps medical staffs to direct patients to a specialized team as soon as it is > 3/10.
PALLI-10 score is not optimized because of the large number of patients with a score > 3 in the French anti-cancer centers. In 2014, a team from Centre Fraçois Baclesse (Caen, France) showed that nearly 65% of hospitalized patients in medicine department has a score PALLIA-10 > 3/10. Today, mobile palliative care teams are too small to manage so many patients.
First, it is important to evaluate the prevalence of these patients in France. Description of patients hospitalized in a Center for the Treatment of Cancers should help us to describe the characteristics of patients requiring cares provided by a mobile palliative care team.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Angers, Frankrike, 49933
- Institut de cancérologie de l'ouest
-
Bordeaux, Frankrike, 33076
- Institut Bergonié
-
Caen, Frankrike, 14000
- Centre Francois Baclesse
-
Clermont Ferrand, Frankrike, 63011
- Centre Jean Perrin
-
Lille, Frankrike, 59020
- Centre Oscar Lambret
-
Lyon, Frankrike, 69008
- Centre Leon Berard
-
Marseille, Frankrike, 13009
- Institut Paoli Calmettes
-
Montpellier, Frankrike, 34298
- Institut Regional du Cancer de Montpellier
-
Nice, Frankrike, 06189
- Centre Antoine Lacassagne
-
Paris - Saint Cloud, Frankrike, 75005
- Institut Curie
-
Reims, Frankrike, 51726
- Institut Jean Godinot
-
Rennes, Frankrike, 35000
- Centre Eugene Marquis
-
Strasbourg, Frankrike, 67085
- Centre Paul Strauss
-
Toulouse, Frankrike, 31059
- Institut Universitaire du Cancer de Toulouse Oncopole
-
Vandoeuvre-lès-Nancy, Frankrike, 54519
- Institut de Cancérologie de Lorraine
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- 18-year old or older
- Hospitalized in a conventionnal medical service, including radiotherapy, brachytherapy, palliative care units.
Exclusion Criteria:
- Patient hospitalized in an out-patient service, surgery unit, weekly units
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Proportion of patients with a score greater than 3/10 to questionnaire PALLIA-10 in the population of patients hospitalized in a French cancer center.
Tidsramme: Day 1 of the study
|
Day 1 of the study
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The proportion of patients with a score greater than 5 to questionnaire PALLIA-10
Tidsramme: Day 1 of the study
|
Day 1 of the study
|
|
Proportion of patients already followed-up by a palliative care team
Tidsramme: Day 1 of the study
|
Day 1 of the study
|
|
Mean score to questionnaire PALLIA-10
Tidsramme: Day 1 of the study
|
Day 1 of the study
|
|
Predictive factors of current palliative cares
Tidsramme: Day 1 of the study
|
Day 1 of the study
|
|
Prognostic factors of overall survival
Tidsramme: From Day 1 of the study to the update of survival status (6 months later)
|
From Day 1 of the study to the update of survival status (6 months later)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Gisèle CHVETZOFF, MD, Centre Leon Berard
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PREPA-10
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Neoplasmer
-
Guangzhou First People's HospitalFullført
-
Technische Universität DresdenHar ikke rekruttert ennåMDS (myelodysplastisk syndrom) | CCUS klonal cytopeni av ubestemt betydning | MDS/Myeloproliferative Neoplasm (MPN) overlappingssyndrom | CHIPTyskland
-
Rabin Medical CenterFullførtDesmoid fibromatose | Desmoid | Desmoid fibromatose i huden | Desmoid Neoplasm of Chest Wall | Desmoid-svulst forårsaket av somatisk mutasjon | Aggressive fibromatoser | Fibromatose DesmoidIsrael
-
Chongqing Precision Biotech Co., LtdRekrutteringAML (akutt myeloid leukemi) | BPDCN (blastisk Plasmacytoid Dendritic Cell Neoplasm)Kina
-
Beijing BiotechRekrutteringPerifert T-celle lymfom | T-lymfoblastisk lymfom | Relapset/Refraktær B-celle akutt lymfatisk leukemi | Resistent/refraktær B-celle non-Hodgkin lymfom eller CLL/SLL | Relapserende/Refraktær Multipl Myelom eller Plasmacelleleukemi | Relapset/Refraktær Akutt Myeloid Leukemi, Høyrisiko Myelodysplastisk... og andre forholdKina
-
Prelude TherapeuticsBeiGeneFullførtMarginal sone lymfom | Akutt myeloid leukemi (AML) | Kronisk myelomonocytisk leukemi (CMML) | Myelodysplastisk syndrom (MDS) | T-celle lymfom | Mantelcellelymfom (MCL) | Diffust storcellet B-celle lymfom (DLBCL) | Richters syndrom | Myeloide maligniteter | Aggressiv B-celle non-Hodgkins lymfom (NHL) | Kronisk... og andre forholdForente stater, Canada, Australia, Frankrike, Italia, Storbritannia, Sør -Korea, Tyskland, Polen, Sveits